T1弛豫时间分析预测接受经动脉化疗栓塞的肝细胞癌患者肝功能不全及预后
前瞻性纳入100例初治肝细胞癌患者,TACE前后测量肝脏及肿瘤T1弛豫时间(T1L、T1T)并构建T1com。38例(38%)发生肝功能不全,T1com预测肝功能不全的AUC优于T1L和T1T(0.81 vs 0.76和0.69)。低T1com(≤0.42)患者中位PFS优于高T1com(>0.42)患者(167.0 vs 215.9天,P=0.010)。
要点
- TACE术后38例(38%)发生肝功能不全。
- T1L和T1T均为评估肝功能不全的独立危险因素。
- T1com预测肝功能不全的AUC为0.81,优于T1L(0.76)和T1T(0.69)。
核心结论
- 与广泛使用的临床参数相比,T1在预测TACE术后肝功能不全方面更具能力;根据T1对接受TACE的肝细胞癌患者进行分层可能有助于临床医生制定治疗策略以预防肝功能不全的发生并改善个体预后。
研究设计与样本
- 前瞻性分析100例连续接受TACE的初治肝细胞癌患者,测量TACE前和/或后肝脏T1弛豫时间(T1L)和肿瘤T1弛豫时间(T1T),采用逐步多因素逻辑回归构建T1相关概率指数(T1com);实验室参数为肝功能不全的金标准。
诊断标准与关键数值
- T1com预测肝功能不全的AUC为0.81,T1L的AUC为0.76,T1T的AUC为0.69(T1com vs T1L P=0.007,T1com vs T1T P=0.006)。
临床应用与阅片要点
- T1L和T1T为评估肝功能不全的独立危险因素;低T1com(≤0.42)患者中位PFS为167.0天,优于高T1com(>0.42)患者的215.9天(P=0.010);CTP、BCLC和ALBI评分在预测接受TACE的肝细胞癌患者PFS方面无统计学显著意义(P>0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the value of T1 mapping in predicting hepatic dysfunction and prognosis in patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE).
MATERIAL AND METHODS: 100 consecutive patients with treatment-naive HCC treated with TACE were prospectively analyzed. Clinical, laboratory, and MRI parameters (liver and tumor T1 relaxation times (T1L, T1T)) before and/or following TACE were measured and calculated. Clinical parameters included the Child-Turcotte-Pugh (CTP) classification, Barcelona Clinic Liver Cancer Classification (BCLC) criteria, and albumin-bilirubin (ALBI) score. Laboratory parameters were the gold standard for hepatic dysfunction. T1L and T1T were combined by stepwise multivariate logistic regression to yield a T1-related probability index (T1com) for further analysis. Study endpoints included hepatic dysfunction and progression-free survival (PFS) rate.
RESULTS: 38 patients (38%) were diagnosed with hepatic dysfunction following TACE. There was no significant difference in clinical parameters between the groups with and without hepatic dysfunction. Logistic regression analysis showed that T1L and T1T were independent risk factors for assessing hepatic dysfunction. T1com showed a better AUC than T1L and T1T (0.81 vs. 0.76 and 0.69, P = 0.007 and 0.006). Patients with low T1com (≤0.42) showed a better median PFS than patients with high T1com (>0.42) (167.0 vs. 215.9 days, P = 0.010). In comparison, CTP, BCLC, and ALBI scores were not statistically significant in predicting PFS in HCC patients treated with TACE (P > 0.05).
CONCLUSION: Compared with widely used clinical parameters, T1 was more capable of predicting hepatic dysfunction after TACE. Stratification of patients with HCC undergoing TACE according to T1 may help clinicians to develop treatment strategies in preventing the occurrence of hepatic dysfunction and improving individual prognoses.
引用
- Huang, Qiao, Jiang, et al. T1 relaxation time analysis in predicting hepatic dysfunction and prognosis in patients with HCC undergoing transarterial chemoembolization. Eur J Radiol. 2023. PMID: 37392548. doi:10.1016/j.ejrad.2023.110938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。